ALX Oncology Holdings Inc. (NASDAQ:ALXO) to post earnings of ($0.76) per share in Q3 2024, Lifesci Capital forecasts

ALX Oncology Holdings Inc. (NASDAQ:ALXO – Free Report) – Equities research analysts at Lifesci Capital upped their Q3 2024 earnings per share (EPS) estimates for ALX Oncology in a report issued on Monday, August 12th. Lifesci Capital analyst S. Slutsky now anticipates that the company will post earnings per share of ($0.76) for the quarter, up from their prior forecast of ($0.78). Lifesci Capital currently has a “Hold” rating on the stock. The consensus estimate for ALX Oncology’s current full-year earnings is ($2.89) per share. Lifesci Capital also issued estimates for ALX Oncology’s Q4 2024 earnings at ($0.73) EPS and FY2024 earnings at ($2.97) EPS.

ALXO has been the subject of several other reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a research note on Monday. Stifel Nicolaus restated a “hold” rating and set a $3.00 target price (down from $5.00) on shares of ALX Oncology in a report on Friday, August 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of ALX Oncology in a report on Tuesday. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Moderate Buy” and an average target price of $17.83, according to MarketBeat.com.

See our latest analysis of ALX Oncology

ALX Oncology trading up 4.8%

NASDAQ:ALXO opened at $2.64 on Wednesday. ALX Oncology has a 52-week low of $2.42 and a 52-week high of $17.83. The stock has a market cap of $137.54 million, a price-to-earnings ratio of -0.71 and a beta of 1.06. The company’s 50-day moving average price is $6.11 and its 200-day moving average price is $11.26. The company has a quick ratio of 5.21, a current ratio of 5.21, and a debt-to-equity ratio of 0.06.

ALX Oncology (NASDAQ:ALXO – Get Your Free Report ) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.01.

Hedge Funds Leverage ALX Oncology

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of ALX Oncology in the fourth quarter valued at approximately $28,000. abrdn plc bought a new stake in ALX Oncology in the 4th quarter valued at about $986,000. Jump Financial LLC purchased a new position in ALX Oncology in the fourth quarter valued at about $371,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of ALX Oncology in the fourth quarter valued at $215,000. Finally, TD Asset Management Inc acquired a new position in shares of ALX Oncology during the fourth quarter valued at $1,048,000. 97.97% of the shares are currently held by hedge funds and other institutional investors.

Insider Buying and Selling at ALX Oncology

In other news, insider Jaume Pons sold 20,000 shares of the business’s stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $8.43, for a total value of $168,600.00. Following the transaction, the insider now directly owns 604,205 shares in the company, valued at approximately $5,093,448.15. The transaction was disclosed in a filing with the SEC, which is accessible via this link. In other news, insider Jaume Pons sold 20,000 shares of the stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $8.43, for a total value of $168,600.00. Following the transaction, the insider now owns 604,205 shares in the company, valued at approximately $5,093,448.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available on the SEC’s website. Also, CFO Peter S. Garcia purchased 12,000 shares of the business’s stock in a transaction that occurred on Thursday, June 13th. The stock was acquired at an average cost of $8.53 per share, for a total transaction of $102,360.00. Following the purchase, the chief financial officer now owns 122,348 shares of the company’s stock, valued at approximately $1,043,628.44. Disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 46,469 shares of company stock worth $363,666. Insiders own 33.40% of the company’s shares.

About ALX Oncology

(Get a free report)

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, is focused on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47-blocking biologic, being developed as a combination therapy with other anti-cancer agents, including ASPEN-06, in a Phase 2 clinical trial for the treatment of gastric/GEJ cancer; ASPEN-07, in the phase 1 clinical trial for the treatment of urothelial cancer; and ASPEN-03 and ASPEN-04, both in phase 2 clinical trials for the treatment of head and neck squamous cell carcinoma.

Featured stories

Get news and reviews for ALX Oncology Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ALX Oncology and related companies with MarketBeat.com’s FREE daily email newsletter.